Lipotec SA has introduced an active that aims to increase fatty tissue volume in areas such as breasts and cheeks. Adifyline (INCI: Butylene Glycol (and) Water (aqua) (and) Acetyl Hexapaptide-38) is said to promote the expression of peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) to enhance the adipogenisis rate.
PGC-1α is a transcriptional coactivator that interacts with the peroxisome proliferator-activated receptor (PPARγ) to modulate adipogenesis. An increased adipogenesis rate is said to result in higher lipid accumulation and volume growth in adipose tissues.
The active is recommended at 2% in facial redefining or breast firming formulations in addition to any product where a replenishing effect is desired. It is a transparent solution containing 0.05% active ingredient. It is soluble in water, ethanol and glycols.
In vitro testing conducted by the company showed a 61% promotion of PGC-1α expression and a higher lipid accumulation in cells. In addition, in vivo testing showed a 12% increase in cheek volume after 14 days of treatment with the active and a 30-fold improvement in breast volume compared to a placebo after 56 days.
